References

HIV infection in older patients

10.1086/374871 · 2003 · External reference

HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient

10.1016/s0047-6374(97)01888-5 · 1997 · External reference

Progress in HIV therapeutics and the challenge of adherence to antiretroviral therapy

10.1016/s0891-5520(05)70139-2 · 2000 · External reference

10.1001/jama.288.2.222

10.1001/jama.288.2.222 · External reference

Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure

10.1097/00042560-200007010-00007 · 2000 · External reference

Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy

10.1097/00002030-200005050-00006 · 2000 · External reference

The cost of HIV treatment and care. A global review

10.2165/00019053-200119010-00002 · 2001 · External reference

Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO Cohort (1988–1994)

10.1093/ije/26.6.1340 · 1997 · External reference

Thymic involution and HIV progression

10.1016/s0167-5699(99)01516-9 · 1999 · External reference

Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the patogenesis of antiretroviral therapy-related lipodystrophy

10.1016/s0140-6736(99)06102-4 · 1999 · External reference

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

10.1046/j.0306-5251.2001.01452.x · 2001 · External reference

Human immunodeficiency virus infection in elderly patients

10.1097/00007611-200194040-00008 · 2001 · External reference

Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection

10.1086/318078 · 2001 · External reference

Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART

10.1097/00002030-200304110-00010 · 2003 · External reference

Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy

10.1016/s0924-8579(03)00100-6 · 2003 · External reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

10.1097/00002030-199807000-00003 · 1998 · External reference

Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen

10.1097/00002030-200001280-00001 · 2000 · External reference

Unresolved reference

External reference

Race, sex, drug use, and progression of human immunodeficiency virus disease

10.1056/nejm199509213331202 · 1995 · External reference

Factors affecting adherence to antiretroviral therapy

10.1086/313849 · 2000 · External reference

Newly diagnosed HIV infection in an octgenarian: the elder are not “immune”

10.1093/ageing/32.3.353 · 2003 · External reference

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

10.1086/315334 · 2000 · External reference

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy

10.1001/jama.283.2.205 · 2000 · External reference

Evidence for thymic function in the elderly

10.1016/s0264-410x(99)00499-5 · 2000 · External reference

Changes in thymic function with age and during the treatment of HIV infection

10.1038/25374 · 1998 · External reference

Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adults AIDS Clinical Trial Group Cardiovascular Disease Focus Group

10.1086/317429 · 2000 · External reference

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial

10.1016/s0140-6736(98)12291-2 · 1999 · External reference

Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic

10.1097/00002030-200003310-00012 · 2000 · External reference

Correlates of service utilization among midlife and older adults with HIV/AIDS: the role of age in equation

10.1177/08964302014003001 · 2002 · External reference

Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies

1999 · External reference

Salvage antiretroviral therapy

2000 · External reference

A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection

10.1089/08892220050195775 · 2000 · External reference

The cost effectiveness of combination antiretroviral therapy for HIV disease

10.1056/nejm200103153441108 · 2001 · External reference

Costs of HIV medical care in the era of highly active antiretroviral therapy

10.1097/00002030-199905280-00013 · 1999 · External reference

Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy

10.1097/00042560-200106010-00009 · 2001 · External reference

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine

10.1097/00002030-200003100-00014 · 2000 · External reference

Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy

10.1097/00002030-200108170-00017 · 2001 · External reference

Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor

10.1097/00002030-200001280-00009 · 2000 · External reference

Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review

10.1097/00042560-200010001-00002 · 2000 · External reference

Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

10.1056/nejm199709113371102 · 1997 · External reference

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

10.1086/317541 · 2001 · External reference

Clinical utility of testing human immunodeficiency virus for drug resistance

10.1086/313861 · 2000 · External reference

Hit HIV-1 hard, but only when necessary

10.1016/s0140-6736(00)02388-6 · 2000 · External reference

Drug susceptibility in HIV infection after viral rebound in patients receiving indivinavir-containing regimens

10.1001/jama.283.2.229 · 2000 · External reference

Analysis of the adult thymus in reconstruction of T lymphocytes in HIV-1 infection

10.1172/jci5201 · 1999 · External reference

Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity

10.1212/01.wnl.0000038347.48137.67 · 2002 · External reference

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy

10.1097/00002030-199911120-00019 · 1999 · External reference

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

10.1086/313843 · 2000 · External reference

Is age a negative prognostic indicator in HIV infection or AIDS?

1999 · External reference

Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients

10.1097/00002030-200005050-00004 · 2000 · External reference

Economic costs of HIV/AIDS prevention activities in sub-Saharan Africa

2000 · External reference

AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment

10.1097/00002030-199902040-00015 · 1999 · External reference

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. The Swiss HIV Cohort Study

10.1001/jama.282.23.2220 · 1999 · External reference

HIV among older adults: age specific issues in prevention and management

2000 · External reference

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

10.7326/0003-4819-131-2-199907200-00002 · 1999 · External reference

Management of dyslipidemia in patients with HIV disease

10.1046/j.1469-0691.2000.00163.x · 2000 · External reference

Evolution of HIV disease in the third millennium: clinical and related economic issues

10.1016/s0924-8579(01)00494-0 · 2002 · External reference

10.1097/00002030-200310170-00014

10.1097/00002030-200310170-00014 · External reference

A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age

10.1097/00002030-200007070-00034 · 2000 · External reference

Switch to an antiretroviral treatment of expected lower potency after effective highly active antiretroviral therapy

10.1097/00042560-200001010-00014 · 2000 · External reference

Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate

10.1053/jinf.2001.0829 · 2001 · External reference

Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study

10.1258/0956462011916839 · 2001 · External reference

The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review

10.1023/a:1007156027134 · 1999 · External reference

Lack of change in the distribution of AIDS-defining opportunistic diseases and the related degree of immunodeficiency during the periods before and after the introduction of highly active antiretroviral therapy

10.1007/s100960100494 · 2001 · External reference

Gynecomastia associated with highly active antiretroviral therapy

10.1345/aph.10274 · 2001 · External reference

HIV disease among immigrants coming to Italy from outside of the European Union: a case-control study of epidemiological and clinical features

10.1017/s0950268801006227 · 2001 · External reference

Three to seven concurrent AIDS-defining disorders at first hospitalization of AIDS presenters as an unexpected emerging feature during the era of highly active antiretroviral therapy

10.1097/00002030-200211220-00025 · 2002 · External reference

A prospective case-control survey of laboratory markers of skeletal muscle damage during HIV disease and antiretroviral therapy

10.1097/00002030-200209270-00018 · 2002 · External reference

10.1016/s0399-077x(03)00235-x

10.1016/s0399-077x(03)00235-x · External reference

Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly

10.1097/00126334-200305010-00016 · 2003 · External reference

A Frequency, risk factors, and features of hyperlactatemia in a large number of patients undergoing antiretroviral therapy

10.1097/00002030-200309260-00019 · 2003 · External reference

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine

10.1097/00002030-199905070-00009 · 1999 · External reference

HIV-associated lipodystrophy syndrome

2000 · External reference

Management of the adverse effects of antiretroviral therapy and medication adherence

10.1086/313859 · 2000 · External reference

Lactic acidosis and hepatic steatosis associated with use of stavudine administration: report of four cases

10.7326/0003-4819-133-3-200008010-00010 · 2000 · External reference

Reasons for modification and discontinuation of antiretroviral therapy. Results from a single treatment centre

10.1097/00002030-200101260-00007 · 2001 · External reference

Cost effectiveness of combination HIV therapy: three years later

10.2165/00019053-200017040-00002 · 2000 · External reference

Principles and practice of HIV-protease inhibitor pharmacoenhancement

10.1046/j.1468-1293.2001.00063.x · 2001 · External reference

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

10.1097/00042560-200001010-00005 · 2000 · External reference

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1

10.1086/314703 · 1999 · External reference

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

10.1097/00002030-200101050-00002 · 2001 · External reference

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency type 1-infected patients: the changes in opportunistic prophylaxis study

10.1086/315471 · 2000 · External reference

Quality of life in maintenance vs. prolonged induction therapy for HIV

10.1001/jama.284.2.178 · 2000 · External reference

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy

10.1097/00002030-199902040-00008 · 1999 · External reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection

10.1056/nejm199803263381301 · 1998 · External reference

Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART

10.1016/s0166-3542(00)00062-0 · 2000 · External reference

Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study

10.1001/archinte.160.8.1123 · 2000 · External reference

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

10.7326/0003-4819-133-1-200007040-00004 · 2000 · External reference

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors

10.1161/01.cir.100.7.700 · 1999 · External reference

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients

10.1056/nejm199810293391802 · 1998 · External reference

Function of the thymus in HIV-infected adults

10.1001/jama.282.3.219 · 1999 · External reference

Mortality for liver disease in patients with HIV infection: a cohort study

10.1097/00042560-200007010-00003 · 2000 · External reference

Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study

10.1097/00042560-199801001-00005 · 1998 · External reference

Recurrent “migrainelike” episodes in patients with HIV disease

10.1046/j.1526-4610.1997.3707443.x · 1997 · External reference

Fat redistribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study

10.1097/00002030-200001070-00005 · 2000 · External reference

Understanding delay to medical care for HIV infection: the long-term non-presenter

10.1097/00002030-200101050-00012 · 2001 · External reference

Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in Nwe York City

10.1086/343048 · 2002 · External reference

Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response

10.1097/00042560-200003010-00002 · 2000 · External reference

Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine and ritonavir therapy

10.1086/315169 · 2000 · External reference

The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load

10.1016/s0163-4453(98)94351-1 · 1998 · External reference

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults

10.1056/nejm199912163412501 · 1999 · External reference

Sexually transmitted diseases in the older population in Singapore

2002 · External reference

Elevated lactate levels in hospitalized persons with HIV infection

10.1089/088922201750063106 · 2001 · External reference

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

10.1097/00002030-200003100-00005 · 2000 · External reference

10.1086/313848

10.1086/313848 · External reference

Incidence of liver toxicity in HIV-infected patients receiving isolated dual nucleoside analogue antiretroviral therapy

10.1097/00126334-200308010-00019 · 2003 · External reference

Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume

10.1097/00002030-200002180-00007 · 2000 · External reference

Stavudine and the peripheral nerve in HIV-1 infected patients

10.1007/s004150050336 · 1999 · External reference

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodefiency virus type 1-infected persons

10.1086/314675 · 1999 · External reference

Overlooked, ignored and forgotten: older women at risk for HIV infection and AIDS

10.1177/0164027598206007 · 1998 · External reference

Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy

10.1084/jem.190.5.725 · 1999 · External reference